Bouncing Back From Trial Failure , Travere Wins First FDA Approval in Rare Kidney Disease
Case Summary
Travere Therapeutics has achieved a significant milestone with the FDA approval of Filspari, the first therapy approved to treat focal segmental glomerulosclerosis (FSGS), a rare kidney disease that can lead to kidney failure and the need for organ transplantation. This once-daily pill is approved for patients aged 8 and older and represents a breakthrough in addressing a condition with limited treatment options. The approval was granted following a lengthy development process, including a Phase 3 clinical trial program that spanned eight years. Notably, the FDA's decision was based on a revised clinical trial endpoint different from the original goals set by Travere at the program's outset.
Stage
Active litigation
Timeline
1 event
Coverage
1 article
Sources
1
Key Issues
- • FDA regulatory approval process
- • Clinical trial endpoint modification
- • Treatment of rare kidney diseases
- • Drug development challenges in rare diseases
- • Impact of trial design on regulatory outcomes
Case Timeline
1 eventBouncing Back From Trial Failure , Travere Wins First FDA Approval in Rare Kidney Disease
Travere Therapeutics has received FDA approval for its drug Filspari, marking the first treatment for the rare kidney disease focal segmental glomerulosclerosis (FSGS) in patients aged 8 and older. This approval is significant because it came after the company adjusted its clinical trial goals following earlier setbacks, ultimately providing a new option for patients facing severe kidney damage. Filspari offers hope for those at risk of kidney failure and the need for organ transplants.